Morgan Stanley’s Biotech Acquisition Company Unit BIOTU Stock Holding History

Morgan Stanley’s Portfolio BIOTU Stock Details BIOTU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-551	Closed	-$5.53K	–	7965
2022 Q4	$5.53K	Hold	551	–	–	﹤0.01%	7121
2022 Q3	$5K	Sell	551 -4,296	-89%	-$42.5K	﹤0.01%	7277
2022 Q2	$48K	Sell	4,847 -3,600	-43%	-$35.6K	﹤0.01%	6637
2022 Q1	$83K	Hold	8,447	–	–	﹤0.01%	6445
2021 Q4	$85K	Hold	8,447	–	–	﹤0.01%	6538
2021 Q3	$85K	Sell	8,447 -1,475	-15%	-$14.8K	﹤0.01%	6467
2021 Q2	$100K	Hold	9,922	–	–	﹤0.01%	6359
2021 Q1	$98K	Buy	+9,922	New	+$102K	﹤0.01%	6024

Morgan Stanley's BIOTU Position: Q1 2023 in Review

Morgan Stanley sold out of Biotech Acquisition Company Unit (BIOTU) in Q1 2023, closing a stake of 551 shares — an estimated $5.53K sold.

Morgan Stanley first reported a position in BIOTU in Q1 2021 and held it in 8 quarters. The position peaked at $100K in Q2 2021. 0 funds tracked by Wall St. Rank hold BIOTU as of Q1 2023.

Morgan Stanley reported no remaining Biotech Acquisition Company Unit position as of Q1 2023 after selling out during the quarter.
Morgan Stanley sold 551 Biotech Acquisition Company Unit shares in Q1 2023, an estimated $5.53K.
Morgan Stanley first reported a position in Biotech Acquisition Company Unit in Q1 2021 and held it in 8 quarters.
Morgan Stanley's Biotech Acquisition Company Unit position peaked at $100K in Q2 2021.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Unit as of Q1 2023.

Based on Morgan Stanley's 13F filing for Q1 2023, filed 15 May 2023.